NLRP3 and heart failure: MCC950 lowered doxorubicin-induced myocardial injury by repressing NLRP3-mediated pyroptosis in in-vivo and in-vitro models (Zhang et al. 2021b) as well as alleviated heart failure-induced ventricular arrhythmia (Jiang et al. 2022).